In May, the FDA granted 5 significant drug approvals across various therapeutic areas, marking notable progress in expanding treatment options for patients.

Panelists discuss key findings supporting the use of MEK inhibitors, such as selumetinib, in treating NF1-associated plexiform neurofibromas, emphasizing its impact on clinical decision-making, ...

A panelist discusses how ITP diagnosis remains one of exclusion requiring thorough testing to rule out other causes of thrombocytopenia, followed by patient education about autoimmune diseases and ...

Tariff increases threaten the US economy and health care costs, impacting managed care affordability and member financial ...

To truly shift the landscape in obesity care, explains Jaime Almandoz, MD, MBA, UT Southwestern, care models and policies ...

Patients with myelodysplastic syndrome (MDS) who received luspatercept showed greater hemoglobin gains and transfusion ...

Congress, convening virtually and in Milan, Italy, from June 12 to June 15, 2025, will feature a revamped program structure ...

Panelists discuss how splice modifiers work by enhancing protein production from the SMN2 gene, with risdiplam (Evrysdi) ...

The PURPOSE trials illuminated the ways in which lenacapavir could be used as a means of pre-exposure prophylaxis effectively, but also featured several adverse events.

Panelists discuss how disease progression despite treatment in older patients with spinal muscular atrophy (SMA) may be due to natural aging effects combined with SMA, not necessarily treatment ...

HHS budget slashes National Institutes of Health (NIH) funding by 40%, alarming health experts and threatening vital research ...

Men’s Health Month 2025 encourages men to adopt preventive care and healthy lifestyle habits to improve overall health ...